Tempus AI, Inc.
TEM · NASDAQ
Company research
Tempus AI, Inc. (NASDAQ: TEM) is a Chicago-based healthcare technology company founded in 2015 that leverages artificial intelligence and one of the world's largest multimodal clinical and molecular data libraries — encompassing approximately 8 million de-identified patient records — to advance precision medicine across oncology, cardiology, neurology, psychiatry, and beyond. The company operates through two primary revenue segments: a genomics diagnostics business offering next-generation sequencing (NGS), PCR profiling, and molecular pathology tests through platforms such as Hub and its core xT/xR assays, and a Data & Services segment that licenses de-identified clinical and molecular data via its Insights product to 19 of the top 20 global pharmaceutical companies, supports clinical trial recruitment through its Trials platform, and provides AI-driven analytics tools including Lens, Algos, and Next. Tempus partners with more than half of U.S. oncologists and maintains strategic collaborations with major biopharma leaders including AstraZeneca, GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, underscoring its critical role as infrastructure for personalized care and drug development. Having gone public in June 2024 at a valuation exceeding $6 billion, the company reported approximately $955 million in revenue for 2025 and a Q1 2026 revenue of $348.1 million — reflecting 36.1% year-over-year growth — as it progresses toward its full-year 2026 adjusted EBITDA target of $65 million.
Research reports
This AI-generated investment thesis evaluates whether Tempus AI’s FDA-cleared genomics and cardiac AI products can translate into durable adoption, revenue scale, and margin improvement before losses, litigation, cloud-cost escalation, and a large accumulated deficit undermine the story. It scores management, business model, growth, and risk, highlighting major data partnerships (AstraZeneca, GSK, Pathos), rising cloud and SBC-related dilution, and frames the stock as a high-potential but high-risk platform where execution and regulatory outcomes remain uncertain.
Flash / StockSentinel · May 8, 2026Tempus AI, Inc. (TEM) Research ReportThis comprehensive Flash report presents Tempus as a dual-engine business (Diagnostics plus Data & Applications) creating a high-margin “data flywheel,” with a 500+ petabyte multimodal dataset, deep U.S. oncology penetration, and growing foundation-model collaborations, supported by strong Q1 2026 revenue growth and improving non-GAAP margins. It lays out detailed moat analysis, TAM, multi-scenario valuation with positive probability-weighted upside, and emphasizes that while profitability, debt, litigation, regulatory scrutiny, and insider selling introduce volatility and dilution risk, the long-term strategic positioning in AI-enabled precision medicine is attractive.
R. Dennis (OpportunityCosts Substack) · November 22, 2025Tempus AI (TEM): Comprehensive Investment Analysis, Valuation, and Strategic OutlookThis analyst-style Substack report reconstructs five years of Tempus AI’s financials and strategy, explaining the “intelligent diagnostics flywheel,” major acquisitions (Ambry Genetics, Paige.AI), competitive positioning versus Foundation Medicine and Guardant Health, and the evolution from lab-centric to data-centric economics with expanding gross margins. Using detailed DCF and IRR modeling, it concludes the shares are roughly fairly valued with a “Neutral / Accumulate on Weakness” stance, stressing the strength of the data moat and pharma relationships while flagging high stock-based compensation and dilution, LDT regulatory risk, data privacy concerns, and customer concentration as key constraints.
Global Achemistica Inc · August 18, 2025Short Report – Tempus AI, Inc. (NASDAQ: TEM)This activist short report argues Tempus AI is a fast-growing but capital-dependent and litigation-exposed company, highlighting heavy cash burn, large M&A outlays, reliance on shelf registration and convertible debt, continuing GAAP losses, and valuation levels that assume optimistic growth and benign legal outcomes. It dissects the business into Genomics and Data & Services segments, underscores patent suits from Guardant Health, questions the durability of Tempus’s data moat and non-exclusive partnerships, and concludes the risk/reward is asymmetric to the downside, maintaining a short bias and bearish outlook on TEM.